PlusPedia wird derzeit technisch modernisiert. Aktuell laufen Wartungsarbeiten. Für etwaige Unannehmlichkeiten bitten wir um Entschuldigung; es sind aber alle Artikel zugänglich und Sie können PlusPedia genauso nutzen wie immer.

Neue User bitte dringend diese Hinweise lesen:

Anmeldung - E-Mail-Adresse Neue Benutzer benötigen ab sofort eine gültige Email-Adresse. Wenn keine Email ankommt, meldet Euch bitte unter NewU25@PlusPedia.de.

Hinweis zur Passwortsicherheit:
Bitte nutzen Sie Ihr PlusPedia-Passwort nur bei PlusPedia.
Wenn Sie Ihr PlusPedia-Passwort andernorts nutzen, ändern Sie es bitte DORT bis unsere Modernisierung abgeschlossen ist.
Überall wo es sensibel, sollte man generell immer unterschiedliche Passworte verwenden! Das gilt hier und im gesamten Internet.
Aus Gründen der Sicherheit (PlusPedia hatte bis 24.07.2025 kein SSL | https://)

Bei PlusPedia sind Sie sicher: – Wir verarbeiten keine personenbezogenen Daten, erlauben umfassend anonyme Mitarbeit und erfüllen die Datenschutz-Grundverordnung (DSGVO) vollumfänglich. Es haftet der Vorsitzende des Trägervereins.

PlusPedia blüht wieder auf als freundliches deutsches Lexikon.
Wir haben auf die neue Version 1.43.3 aktualisiert.
Wir haben SSL aktiviert.
Hier geht es zu den aktuellen Aktuelle Ereignissen

Clin Appl Thromb Hemost

Aus PlusPedia
Zur Navigation springen Zur Suche springen

[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83][84][85][86][87][88][89][90][91][92][93][94]

Clincal and Applied Thrombosis and Hemostasis
SUCHEN
Frei verfügbar öffnet sporadisch
Pubmed von 1994-1998 nicht erfaßt
Impact Factor
Charakteristik Hämostaseologie
Übersichtsartikel in Pluspedia
  1. ↑ Nontraditional risk factors in carotid artery disease. Clin Appl Thromb Hemost 16(5):554-8 (2010) PMID 20460338
  2. ↑ Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism. Clin Appl Thromb Hemost 16(3):318-25 (2010) PMID 19221100
  3. ↑ Lessons from ximelagatran: issues for future studies evaluating new oral direct thrombin inhibitors for venous thromboembolism prophylaxis in orthopedic surgery. Clin Appl Thromb Hemost 15(3):316-26 (2009) PMID 19028773
  4. ↑ Glanzmann's thrombasthenia: an overview. Clin Appl Thromb Hemost 15(2):152-65 (2009) PMID 18930954
  5. ↑ Coagulation activation by lipopolysaccharides. Clin Appl Thromb Hemost 15(2):209-19 (2009) PMID 18160570
  6. ↑ Use of recombinant activated factor VII to arrest uncontrolled bleeding: a case series. Clin Appl Thromb Hemost 15(2):225-32 (2009) PMID 18160562
  7. ↑ Management of uremic patients with heparin-induced thrombocytopenia requiring hemodialysis. Clin Appl Thromb Hemost 14(4):459-64 (2008) PMID 18160571
  8. ↑ Serologic results in >1000 patients with suspected heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 14(4):410-4 (2008) PMID 17895512
  9. ↑ Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosis. Clin Appl Thromb Hemost 14(3):360-4 (2008) PMID 18160568
  10. ↑ Rectus sheath hematoma due to inappropriate warfarin usage. Clin Appl Thromb Hemost 14(1):116-7 (2008) PMID 18182681
  11. ↑ Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb Hemost 13(2):182-7 (2007) PMID 17456628
  12. ↑ Thromboembolism in cancer patients: pathogenesis and treatment. Clin Appl Thromb Hemost 12(3):254-66 (2006) PMID 16959679
  13. ↑ Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb Hemost 12(2):205-12 (2006) PMID 16708123
  14. ↑ Warfarin-induced skin necrosis: a case report. Clin Appl Thromb Hemost 12(1):101-4 (2006) PMID 16444443
  15. ↑ Extreme thrombocytosis: what are the etiologies? Clin Appl Thromb Hemost 12(1):85-7 (2006) PMID 16444439
  16. ↑ Evaluation of a rapid automated assay for analysis of von Willebrand ristocetin cofactor activity. Clin Appl Thromb Hemost 12(1):61-7 (2006) PMID 16444436
  17. ↑ Antiphospholipid-mediated thrombosis: interplay between anticardiolipin antibodies and vascular cells. Clin Appl Thromb Hemost 12(1):41-5 (2006) PMID 16444433
  18. ↑ Prevention of edema in long flights with Pycnogenol. Clin Appl Thromb Hemost 11(3):289-94 (2005) PMID 16015414
  19. ↑ Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy. Clin Appl Thromb Hemost 8(4):359-67 (2002) PMID 12516686
  20. ↑ Thrombolytic therapy. Clin Appl Thromb Hemost 8(4):291-314 (2002) PMID 12516680
  21. ↑ Association of platelet-derived microparticles with C-C chemokines on vascular complication in patients with acute myocardial infarction. Clin Appl Thromb Hemost 8(3):279-86 (2002) PMID 12361207
  22. ↑ Plasma levels of heparin cofactor II (HCII) and thrombin-HCII complex in patients with disseminated intravascular coagulation. Clin Appl Thromb Hemost 8(3):265-71 (2002) PMID 12361205
  23. ↑ Effect of hemodialysis on plasma levels of vascular endothelial markers. Clin Appl Thromb Hemost 8(3):245-50 (2002) PMID 12361202
  24. ↑ Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions. Clin Appl Thromb Hemost 8(3):193-212 (2002) PMID 12361196
  25. ↑ Vascular thrombohemorrhagic disorders: hereditary and acquired. Clin Appl Thromb Hemost 7(3):178-94 (2001) PMID 11441978
  26. ↑ Failure to lyse venous thrombi because of elevated plasminogen activator Inhibitor 1 (PAI-1) and 4G polymorphism of its promotor genome (The PAI-1/4G Syndrome). Clin Appl Thromb Hemost 16(5):574-8 (2010) PMID 20724304
  27. ↑ State-of-the-art review: Hemostats, sealants, and adhesives II: Update as well as how and when to use the components of the surgical toolbox. Clin Appl Thromb Hemost 16(5):497-514 (2010) PMID 20699255
  28. ↑ Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of Ankaferd Blood Stopper. Clin Appl Thromb Hemost 16(4):446-53 (2010) PMID 19833624
  29. ↑ Low dose of argatroban saline flushes anticoagulation in hemodialysis patients with high risk of bleeding. Clin Appl Thromb Hemost 16(4):440-5 (2010) PMID 19833621
  30. ↑ Lipoprotein (a) levels in childhood arterial ischemic stroke. Clin Appl Thromb Hemost 16(2):214-7 (2010) PMID 19752039
  31. ↑ Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers. Clin Appl Thromb Hemost 16(1):60-5 (2010) PMID 19117965
  32. ↑ Effect of recombinant activated factor VII in critical bleeding: clinical experience of a single center. Clin Appl Thromb Hemost 15(6):628-35 (2009) PMID 19605376
  33. ↑ Acute massive pulmonary embolism with hemodynamic compromise treated successfully with thrombolytic therapy. Clin Appl Thromb Hemost 15(6):708-10 (2009) PMID 18818230
  34. ↑ Use of aspirin versus clopidogrel plus aspirin after coronary artery bypass graft surgery. Clin Appl Thromb Hemost 15(5):540-4 (2009) PMID 19088098
  35. ↑ Pleiotropic effects of heparin and heparinoids in peritoneal dialysis. Clin Appl Thromb Hemost 15(1):92-7 (2009) PMID 18160609
  36. ↑ Further insight into the heparin-releasable and glycosylphosphatidylinositol-lipid--anchored forms of tissue factor pathway inhibitor. Clin Appl Thromb Hemost 14(3):267-78 (2008) PMID 18160611
  37. ↑ Ocular vascular thrombotic events: central retinal vein and central retinal artery occlusions. Clin Appl Thromb Hemost 14(3):286-94 (2008) PMID 18160589
  38. ↑ Heparin-induced thrombocytopenia complicating hemodialysis. Clin Appl Thromb Hemost 14(1):105-7 (2008) PMID 18160608
  39. ↑ Homocysteine activates platelets in vitro. Clin Appl Thromb Hemost 14(1):8-18 (2008) PMID 18160593
  40. ↑ Singlet oxygen potentiates thrombolysis. Clin Appl Thromb Hemost 13(3):259-78 (2007) PMID 17636188
  41. ↑ Evaluation of off-label recombinant activated factor VII for multiple indications in children. Clin Appl Thromb Hemost 13(3):233-40 (2007) PMID 17636185
  42. ↑ Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Clin Appl Thromb Hemost 12(4):397-420 (2006) PMID 17000885
  43. ↑ Diabetic ulcers: microcirculatory improvement and faster healing with pycnogenol. Clin Appl Thromb Hemost 12(3):318-23 (2006) PMID 16959685
  44. ↑ The role of adiponectin in atherosclerosis and thrombosis. Clin Appl Thromb Hemost 12(2):163-8 (2006) PMID 16708117
  45. ↑ Thrombin generation by exposure of blood to endotoxin: a simple model to study disseminated intravascular coagulation. Clin Appl Thromb Hemost 12(2):137-61 (2006) PMID 16708116
  46. ↑ Hereditary and acquired thrombophilic disorders. Clin Appl Thromb Hemost 12(2):125-35 (2006) PMID 16708115
  47. ↑ Effects of high-dose methylprednisolone therapy on coagulation factors in patients with acute immune thrombocytopenic purpura. Clin Appl Thromb Hemost 11(4):489-92 (2005) PMID 16244777
  48. ↑ Clinico-hematologic profile of factor XIII-deficient patients. Clin Appl Thromb Hemost 11(4):475-80 (2005) PMID 16244775
  49. ↑ Plasma levels of thrombin-activatable fibrinolysis inhibitor in primary and secondary thrombocytosis. Clin Appl Thromb Hemost 11(4):449-54 (2005) PMID 16244771
  50. ↑ Idiopathic intracranial hypertension: associations with thrombophilia and hypofibrinolysis in men. Clin Appl Thromb Hemost 11(4):441-8 (2005) PMID 16244770
  51. ↑ The role of plasma exchange in HELLP syndrome. Clin Appl Thromb Hemost 11(2):211-7 (2005) PMID 15821828
  52. ↑ The increase of blood anticardiolipin antibody depends on the underlying etiology in cerebral ischemia. Clin Appl Thromb Hemost 11(2):203-10 (2005) PMID 15821827
  53. ↑ Clinicohematologic spectrum in patients with lupus anticoagulant. Clin Appl Thromb Hemost 11(2):191-5 (2005) PMID 15821825
  54. ↑ Platelet CD61 might have an important role in causing hemorrhagic complication in dengue infection. Clin Appl Thromb Hemost 11(1):112 (2005) PMID 15678283
  55. ↑ Argatroban treatment for patients with intolerance to heparin and hirudin. Clin Appl Thromb Hemost 11(1):99-103 (2005) PMID 15678280
  56. ↑ Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly. Clin Appl Thromb Hemost 11(1):15-23 (2005) PMID 15678269
  57. ↑ Endothelial injury markers with high-dose intravenous iron therapy in renal failure. Clin Appl Thromb Hemost 10(4):403-6 (2004) PMID 15497030
  58. ↑ The importance of platelet counts in dengue infection: 35 cases and literature review. Clin Appl Thromb Hemost 10(4):399-402 (2004) PMID 15497029
  59. ↑ Bleeding and other presentations in Thai patients with dengue infection. Clin Appl Thromb Hemost 10(4):397-8 (2004) PMID 15497028
  60. ↑ Prevention of venous thrombosis and thrombophlebitis in long-haul flights with pycnogenol. Clin Appl Thromb Hemost 10(4):373-7 (2004) PMID 15497024
  61. ↑ Hemostatic abnormalities and changes following bone marrow transplantation. Clin Appl Thromb Hemost 10(4):341-50 (2004) PMID 15497020
  62. ↑ Sapheno-femoral junction pathology: molecular mechanism of saphenous vein incompetence. Clin Appl Thromb Hemost 10(4):311-21 (2004) PMID 15497017
  63. ↑ Thrombosis and a hypercoagulable state in HIV-infected patients. Clin Appl Thromb Hemost 10(3):277-80 (2004) PMID 15247986
  64. ↑ Current debates in antiphospholipid syndrome: the acquired antibody-mediated thrombophilia. Clin Appl Thromb Hemost 10(2):89-126 (2004) PMID 15094931
  65. ↑ The altered hemorheologic parameters in thromboangiitis obliterans: a new insight. Clin Appl Thromb Hemost 10(1):45-50 (2004) PMID 14979404
  66. ↑ Decreased protein Z concentrations complicating the hypercoagulable state of Behcet's disease. Clin Appl Thromb Hemost 9(3):259-63 (2003) PMID 14507116
  67. ↑ Glanzmann's thrombasthenia proposed optimal management during surgery and delivery. Clin Appl Thromb Hemost 9(2):167-70 (2003) PMID 12812388
  68. ↑ Flight microangiopathy on long-haul flights: prevention of edema and microcirculation alterations with Venoruton. Clin Appl Thromb Hemost 9(2):109-14 (2003) PMID 12812378
  69. ↑ On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 9(1):25-32 (2003) PMID 12643320
  70. ↑ The LONFLIT4-VENORUTON study: a randomized trial prophylaxis of flight-edema in normal subjects. Clin Appl Thromb Hemost 9(1):19-23 (2003) PMID 12643319
  71. ↑ Hemostatic abnormalities following bone marrow transplantation. Clin Appl Thromb Hemost 8(2):125-32 (2002) PMID 12121052
  72. ↑ The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. Clin Appl Thromb Hemost 8(1):73-6 (2002) PMID 11991243
  73. ↑ Interobserver agreement of complete compression ultrasound for clinically suspected deep vein thrombosis. Clin Appl Thromb Hemost 8(1):45-9 (2002) PMID 11991239
  74. ↑ Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care. Clin Appl Thromb Hemost 8(1):1-31 (2002) PMID 11991236
  75. ↑ Endothelial dysfunction in the pathogenesis of atherosclerosis. Clin Appl Thromb Hemost 7(4):276-80 (2001) PMID 11697708
  76. ↑ Antiphospholipid thrombosis syndromes. Clin Appl Thromb Hemost 7(4):241-58 (2001) PMID 11697705
  77. ↑ Plasma markers of endothelial dysfunction in chronic obstructive pulmonary disease. Clin Appl Thromb Hemost 7(3):205-8 (2001) PMID 11441980
  78. ↑ Lung scintigraphy and helical computed tomography for the diagnosis of pulmonary embolism: a meta-analysis. Clin Appl Thromb Hemost 7(2):87-92 (2001) PMID 11292198
  79. ↑ Erythrocyte aggregation in nonvalvular atrial fibrillation. Clin Appl Thromb Hemost 7(1):75 (2001) PMID 11190910
  80. ↑ Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Clin Appl Thromb Hemost 7(1):5-9 (2001) PMID 11190905
  81. ↑ Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 6(3):157-61 (2000) PMID 10898276
  82. ↑ Effect of sarpogrelate hydrochloride on platelet-derived microparticles and various soluble adhesion molecules in diabetes mellitus. Clin Appl Thromb Hemost 6(3):139-43 (2000) PMID 10898273
  83. ↑ The antithrombotic factor singlet oxygen/light (1O2/h nu). Clin Appl Thromb Hemost 6(1):22-30 (2000) PMID 10726045
  84. ↑ Thrombolytic drugs in acute myocardial infarction. Clin Appl Thromb Hemost 6(1):1-13 (2000) PMID 10726042
  85. ↑ Heparin-induced thrombocytopenia: historical review. Clin Appl Thromb Hemost 5 Suppl 1():S2-6 (1999) PMID 10726029
  86. ↑ Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost 5 Suppl 1():S45-55 (1999) PMID 10726036
  87. ↑ Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation. Clin Appl Thromb Hemost 5 Suppl 1():S38-44 (1999) PMID 10726035
  88. ↑ Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Clin Appl Thromb Hemost 5 Suppl 1():S32-7 (1999) PMID 10726034
  89. ↑ Generation and pathogenicity of anti-platelet factor 4 antibodies: diagnostic implications. Clin Appl Thromb Hemost 5 Suppl 1():S28-31 (1999) PMID 10726033
  90. ↑ Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 5 Suppl 1():S21-7 (1999) PMID 10726032
  91. ↑ Inadequacy of current prevention strategies for heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 5 Suppl 1():S16-20 (1999) PMID 10726031
  92. ↑ Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy. Clin Appl Thromb Hemost 5 Suppl 1():S7-15 (1999) PMID 10726030
  93. ↑ Acquired von Willebrand disease in monoclonal gammapathies: effectiveness of high-dose intravenous gamma globulin. Clin Appl Thromb Hemost 5(3):152-7 (1999) PMID 10726000
  94. ↑ Acquired von Willebrand disease due to increasing platelet count can readily explain the paradox of thrombosis and bleeding in thrombocythemia. Clin Appl Thromb Hemost 5(3):147-51 (1999) PMID 10725999
Abgerufen von „https://h.suprapedia.de/w/index.php?title=Clin_Appl_Thromb_Hemost&oldid=227007“